Advanced Delivery Device Technology to Simplify the Reconstitution of Lyophilized Drugs

In this webinar, originally broadcast as part of Pharmapack Europe 2022, Chris Muenzer, Vice President of Innovation & Development, Haselmeier, a medmix Brand discusses how development of an integrated drug delivery device is a complex exercise that requires expertise in medical device engineering and pharmaceutical science. Health authorities expect legal manufactures to have a strategy to control device performance through the entire supply. Modeling and simulation is an important tool to ensure robust and repeatable performance while maintaining time to market. This case study looks at how Haselmeier is applying these techniques during the creation of a new autoinjector platform. In addition, Chris will look at future opportunities for further improvements though expanded use of digital twins and other technologies.

PiccoJect™ is a highly compact, customizable and fully featured two-step autoinjector designed for subcutaneous delivery of drug products.Extremely low part counrtLarge wrap-around drug window with customizable sizeOptimized spring forcesFuture proofCommitted to sustainabilityErgonomic shape & small sizeColored status indicatorAudible clicks at the start and end of injectionAny standard 1 ml or 2.25 ml pre-filled syringeA full-service platform
The products shown in this video are under development and some of them may not yet have been approved for sale under applicable medical device regulations. The concept provides general information about these products, their field of application and intended use, and their function, performance and specification are subject to customer specific development and may deviate from those shown herein. All information contained herein is directed at medical device manufacturers and pharmaceutical companies. This information shall not constitute a promotion for use in a way which conflicts with any applicable medical device regulations, nor is it directed at patients or intended to replace professional medical advice.

PiccoJect™ is a highly compact, customizable and fully featured two-step autoinjector designed for subcutaneous delivery of drug products.Extremely low part counrtLarge wrap-around drug window with customizable sizeOptimized spring forcesFuture proofCommitted to sustainabilityErgonomic shape & small sizeColored status indicatorAudible clicks at the start and end of injectionAny standard 1 ml or 2.25 ml pre-filled syringeA full-service platform
The products shown in this video are under development and some of them may not yet have been approved for sale under applicable medical device regulations. The concept provides general information about these products, their field of application and intended use, and their function, performance and specification are subject to customer specific development and may deviate from those shown herein. All information contained herein is directed at medical device manufacturers and pharmaceutical companies. This information shall not constitute a promotion for use in a way which conflicts with any applicable medical device regulations, nor is it directed at patients or intended to replace professional medical advice.

Effective self-management of chronic diseases requires healthcare solutions that are easy and convenient for patients. This is one of the key drivers for our patient-focused development of innovative drug delivery solutions.
The simplicity of PiccoJect™, combined with our sustainability philosophy, is reflected in the entire supply chain to reduce waste and minimize environmental impacts. In addition to investing in green electricity and the use of sustainable feedstocks, we focus on the development of regional supply chains for the US and European markets. 'Excellence through simplicity' sums up our patient-centered and sustainable philosophy.


The products shown in this video are under development and some of them may not yet have been approved for sale under applicable medical device regulations. The concept provides general information about these products, their field of application and intended use, and their function, performance and specification are subject to customer specific development and may deviate from those shown herein. All information contained herein is directed at medical device manufacturers and pharmaceutical companies. This information shall not constitute a promotion for use in a way which conflicts with any applicable medical device regulations, nor is it directed at patients or intended to replace professional medical advice.

The D-Flex™ closes a gap in the market: The D-Flex™ injection pen can do more than previous pens. D-Flex™ can be configured for several fixed dose values and is thus a variable fixed dose pen. It makes it possible to integrate a certain dosage value or several different fixed dosage volumes in one injection device.

Haselmeier Manufacturing Site Dnesice, Czech Republic

The D-Flex™ Ecosystem comprises hardware, software and services enabling data capture in clinical trials. In particular, the system consists of the D-Flex™ injection pen, a digital cap, a mobile app and the Haselmeier™ dataplatform. The digital cap captures data at the point of care and securely transfers it to the Haselmeier™ data platform.The platform allows controlled and secure access to the different stakeholders.

Haselmeier Manufacturing Site Bengaluru, India

Operating with patented, Bluetooth (BLE)-enabled, dose-sensing technology, the digital cap measures the dispensed dose, time and temperature, enabling seamless data collection at the point of care. D-Flex™️ Connect is a proven technology that can be adapted to a number of drugs and indications.

Here, Fred Metzmann, PhD, Director Business Development, and Frank Leipold, Business Developer Digital Solutions, at Haselmeier, discuss the benefits of connected medical devices in clinical trials and describe the advantages of Haselmeier's D-Flex® Ecosystem for improving adherence and reducing the dropout rate in clinical trials. 

In this article, Fred Metzmann, PhD, Director Business Development, reports on the latest state-of-the-art developments in innovative injection devices for combination products in subcutaneous self-application. He outlines Haselmeier's product platform strategy for single-use (D-Flex) and re-usable (i-pen²) injection-pen systems, and related services. He also looks at the company’s connected digital solutions, which support point-of-care data collection and transfer by patients, as well as data management by stakeholders in the care environment.

Type 2 diabetes is a global health problem – according to expert estimates, the number of patients worldwide will increase by 48 percent by 2045. constantly elevated blood sugar levels mean stress for the blood vessels,which can lead to feared complications,including life-threatening sequelae such as a heart attack, organ failure or stroke. A consistent treatment of type 2 diabetes as early as possible can significantly improve the quality of life for the patient and the course of the disease.All patients have in common that they have had to treat it on their own their whole lives. A patient-centered approach must be consistently developed so that the GLP-1 analogs treatment is efficient.The innovative D-Flex™ injection pen can make a significant contribution to this.

The International Osteoporosis Foundation cites figures of around 200 million osteoporosis patients worldwide.Numerous patients suffer not just one bone fracture, but several at once. Treatment does not appear to be having the best possible effect. As an experienced partner in the design and production of injection systems, Haselmeier is also well prepared in terms of injection pens for osteoporosis therapy.

This session will explore: The role of the device supplier in overall product sustainability Benefits of lifecycle assessment (LCA) in device development Trade-offs between usability, cost of goods, and carbon footprint Challenging Pharma to close the circle and enable better solutions

Simple patient monitoring for self-injection-based therapies

The D-Flex™ Logbook collects injection data at the point of care without the need for a patient mobile app.

D-Flex™ Logbook – From data to value

The D-Flex™ Logbook consists of the disposable D-Flex™ injection pen and a connected cap, which replaces the standard cap of the pen. Patients remove the connected cap from the injection pen, dial a dose, self-inject and put the cap back on the pen; exactly how they would use a pen and a standard protective cap. Once the patient returns the cap onto the pen, the connected cap automatically identifies the administered dose, the current temperature and time and stores this injection event in its internal memory. The cap can store up to 1,000 injection events.


The products shown in this video are under development and some of them may not yet have been approved for sale under applicable medical device regulations. The content provides general information about these products, their field of application and intended use, and their function, performance and specification are subject to customer specific development and may deviate from those shown herein. All information contained herein is directed at medical device manufacturers and pharmaceutical companies. This information shall not constitute a promotion for use in a way which conflicts with any applicable medical device regulations, nor is it directed at patients or intended to replace professional medical advice.

Test

D-Flex Logbook

This webinar will address: Introduction of HM digital roadmap Presentation of a new smart drug delivery system, which does not require a patient phone/app – the D-Flex Logbook Value of smart drug delivery solutions in clinical testing This webinar originally aired as part of Pharmapack Europe 2021

This webinar will discuss: Past trends in injection devices Challenges in the industry Impact of platforms, digitalization, and sustainability Ways to change how we develop devices This webinar originally aired as part of Pharmapack Europe 2021